CMT Targets Cancer, Prenatal Testing Markets In China
This article was originally published in PharmAsia News
Executive Summary
China Medical Technologies plans to exploit China's efforts to expand health care access by launching prenatal and postnatal tests as well as cancer diagnostics based on newly acquired fluorescent in situ hybridization technology
You may also be interested in...
China Medical Technologies Invests $345 Million In HPV Genotyping Chip
China Medical Technologies is acquiring a human papillomavirus genotyping assay which it expects will generate up to $26.5 million in sales next year
China Medical Technologies Invests $345 Million In HPV Genotyping Chip
China Medical Technologies is acquiring a human papillomavirus genotyping assay which it expects will generate up to $26.5 million in sales next year
China Medical Technologies Weathers Diagnostic Equipment Sales Decline With Reagent Growth
SHANGHAI - China Medical Technologies, an in vitro diagnostic provider in China, has registered a 67.4 percent year-over-year jump in revenues to 915.7 million yuan ($130.6 million) on the back of reagent business growth for FY2007, despite a decline in diagnostic equipment sales, the company announced June 12